Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ballard

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Science Translational Medicine|May 20, 2021
Na<sub>v</sub>1.7 target modulation and efficacy can be measured in nonhuman primate assaysRichard L Kraus, Fuqiang Zhao, Parul S Pall, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of Arylsulfonamide Na<sub>v</sub>1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity ProfileAnthony J Roecker, Mark E Layton, Joseph E Pero, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 13, 2021
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide InhibitorPierre Morissette, Nianyu Li, Jeanine E Ballard, et al.
Journal of Medicinal Chemistry|September 6, 2019
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for TauopathiesHarold G Selnick, J Fred Hess, Cuyue Tang, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|June 2, 2005
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophreniaG B Fox, T A Esbenshade, J B Pan, et al.
Cell Biochemistry and Biophysics|July 8, 2009
Positive allosteric interaction of structurally diverse T-type calcium channel antagonistsVictor N Uebele, Cindy E Nuss, Steven V Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
Journal of Medicinal Chemistry|June 11, 2008
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonistWilliam D Shipe, James C Barrow, Zhi-Qiang Yang, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Science Translational Medicine|May 20, 2021
Na<sub>v</sub>1.7 target modulation and efficacy can be measured in nonhuman primate assaysRichard L Kraus, Fuqiang Zhao, Parul S Pall, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of Arylsulfonamide Na<sub>v</sub>1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity ProfileAnthony J Roecker, Mark E Layton, Joseph E Pero, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 13, 2021
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide InhibitorPierre Morissette, Nianyu Li, Jeanine E Ballard, et al.
Journal of Medicinal Chemistry|September 6, 2019
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for TauopathiesHarold G Selnick, J Fred Hess, Cuyue Tang, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|June 2, 2005
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophreniaG B Fox, T A Esbenshade, J B Pan, et al.
Cell Biochemistry and Biophysics|July 8, 2009
Positive allosteric interaction of structurally diverse T-type calcium channel antagonistsVictor N Uebele, Cindy E Nuss, Steven V Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
Journal of Medicinal Chemistry|June 11, 2008
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonistWilliam D Shipe, James C Barrow, Zhi-Qiang Yang, et al.
Pageof 19